A novel canine favored CpG oligodeoxynucleotide capable of enhancing the efficacy of an inactivated aluminum-adjuvanted rabies vaccine of dog use.
In order to develop novel canine CpG ODNs as adjuvant for rabies vaccine of dog use, a panel of CpG ODNs containing different CpG motifs was designed and screened for their ability to induce the proliferation of canine splenocytes. Three AACGTT motif-containing CpG ODNs, designated as YW07, YW08 and YW09, respectively, were outshined with stronger ability to activate canine immune cells. The CpG ODNs were tested for their adjuvant activity for rabies vaccine in mice and dogs. It was found that YW07 could facilitate the rabies vaccine to induce more vigorous and long-lasting specific antibody response in mice and dogs, respectively. These findings suggest that YW07, a canine favored CpG ODN, could be used as a novel adjuvant for developing more efficient rabies vaccine of dog use.
Ren
Jiling
J
Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China.
Sun
Luguo
L
Yang
Liang
L
Wang
Hua
H
Wan
Min
M
Zhang
Peiyin
P
Yu
Hongtao
H
Guo
Yan
Y
Yu
Yongli
Y
Wang
Liying
L
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000535:Aluminum / Q000008:administration & dosage*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002478:Cells, Cultured; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D007963:Leukocytes, Mononuclear / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage*; D011818:Rabies / Q000517:prevention & control / Q000662:veterinary*; D011819:Rabies Vaccines / Q000276:immunology*; D013154:Spleen / Q000276:immunology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D011819:Rabies Vaccines; D000535:Aluminum